Investors
Press Releases
Coming Soon
Publications
- Chemaly RF, Marty FM, Wolfe CR, Lawrence SJ, Dadwal S, Soave R, Farthing J, Hawley S, Montanez P, Hwang J, Ho J, Lewis S, Wang G, Boeckh M. DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. Clin Infect Dis. 2021 Feb 11:ciab113. doi: 10.1093/cid/ciab113. Epub ahead of print. PMID: 33569576.
- Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R. DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center. Biol Blood Marrow Transplant. 2016 May;22(5):965-70. doi: 10.1016/j.bbmt.2016.02.011. Epub 2016 Feb 22. PMID: 26904972.
- Waghmare A, Wagner T, Andrews R, Smith S, Kuypers J, Boeckh M, Moss R, Englund JA. Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children. J Pediatric Infect Dis Soc. 2015 Jun;4(2):114-8. doi: 10.1093/jpids/piu039. Epub 2014 May 14. PMID: 26185620; PMCID: PMC4501511.
- Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G, Li QX, Wurtman D, Niewiesk S, Fang F. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010 Jul 15;202(2):234-41. doi: 10.1086/653621. PMID: 20533871; PMCID: PMC2891144.
- Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Fry AM, Villanueva J, Gubareva LV. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis. 2014 Aug 1;210(3):435-40. doi: 10.1093/infdis/jiu105. Epub 2014 Feb 25. PMID: 24569063; PMCID: PMC4091581.
- Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012 Dec 15;206(12):1844-51. doi: 10.1093/infdis/jis622. Epub 2012 Oct 8. PMID: 23045618; PMCID: PMC3570175.
- Triana-Baltzer GB, Gubareva LV, Klimov AI, Wurtman DF, Moss RB, Hedlund M, Larson JL, Belshe RB, Fang F. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838. doi: 10.1371/journal.pone.0007838. PMID: 19893749; PMCID: PMC2770896.
- Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim DH, Malakhov MP, Yu M, Fang F, Katz JM. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007 Nov 15;196(10):1493-9. doi: 10.1086/522609. Epub 2007 Oct 31. PMID: 18008229.
- Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006 Apr;50(4):1470-9. doi: 10.1128/AAC.50.4.1470-1479.2006. PMID: 16569867; PMCID: PMC1426979.
- van der Touw W, Chen HM, Pan PY, Chen SH. LILRB receptor-mediated regulation of myeloid cell maturation and function. Cancer Immunol Immunother. 2017 Aug;66(8):1079-1087. doi: 10.1007/s00262-017-2023-x. Epub 2017 Jun 21. PMID: 28638976; PMCID: PMC5591173.
- Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R, Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018 Dec 3;128(12):5647-5662. doi: 10.1172/JCI97570. Epub 2018 Oct 22. PMID: 30352428; PMCID: PMC6264729.
- Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M, Moretta L, Locatelli F, Pende D. NK Cell-Based Immunotherapy for Hematological Malignancies. J Clin Med. 2019 Oct 16;8(10):1702. doi: 10.3390/jcm8101702. PMID: 31623224; PMCID: PMC6832127.
- Quintarelli C, Sivori S, Caruso S, Carlomagno S, Boffa I, Orlando D, Guercio M, Cembrola B, Pitisci A, Cecca SD, Pira GL, Vinti L, Angelis BD, Moretta L, Locatelli F. CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells. Blood (2018) 132 (Supplement 1): 3491. doi: 10.1182/blood-2018-99-118005
- Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17. PMID: 24135899
- Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O’Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8. PMID: 25292189; PMCID: PMC4426804.
- Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O’Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther. 2016 Aug;24(8):1492-501. doi: 10.1038/mt.2016.101. Epub 2016 May 16. PMID: 27203445; PMCID: PMC5023393.
